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Abstract
OBJECTIVE: To investigate the use of Aloe vera (A.
vera) for the treatment of gastroesophageal reflux
disease (GERD) symptoms and compare its effects
with those of omeprazole and ranitidine.
METHODS: In this pilot, randomized controlled tri-
al, 79 subjects were allocated to A. vera syrup (stan-
dardized to 5.0 mg polysaccharide per mL of syrup)
at a dose of 10 mL/d, omeprazole capsule (20 g/d)
or ranitidine tablet (150 mg in a fasted state in the
morning and 150 mg 30 min before sleep at night)
for a period of 4 weeks. The frequencies of eight
main symptoms of GERD (heartburn, food regurgi-
tation, flatulence, belching, dysphagia, nausea,
vomiting and acid regurgitation) were assessed at
weeks 2 and 4 of the trial.
RESULTS: A. vera was safe and well tolerated and
reduced the frequencies of all the assessed GERD
symptoms, with no adverse events requiring with-
drawal.
CONCLUSION: A. vera may provide a safe and effec-
tive treatment for reducing the symptoms of GERD.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Gastroesophageal reflux disease (GERD) is a chronic,
recurrent and progressive disease associated with a wide
range of esophageal (e.g. esophageal ulcer, esophageal
cancer, Barrett's disease) as well as non-esophageal (e.g.
respiratory problems, chest pain, angina) complica-
tions. Mucosal damage caused by gastric refluxate
means that GERD occasionally shows similar symp-
toms to functional dyspepsia and irritable bowel syn-
drome.1
Official statistics suggest that 44% of the population of
the United States experience GERD symptoms at least
once a month, and 20% at least once a week.2,3 The
overall prevalence of GERD in the Western world has
been reported to be about 10%-20%, making it one of
the most common gastrointestinal diseases.4 However,
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despite the high prevalence of GERD, its definitive di-
agnosis and clinical differentiation from other morbidi-
ties is difficult, at least partly because of the presence of
atypical manifestations such as laryngopharngeal re-
flux, chronic cough, asthma and dental erosions.1 Nota-
bly, GERD symptoms have been reported to adversely
affect patients' daily activities and quality of life, and
impose a substantial cost on healthcare systems.5,6
Regarding the recurrent nature of GERD, most pa-
tients require continuous and long-term medication.
Proton pump inhibitors and H2 receptor blockers are
the most commonly prescribed drug classes for GERD.
However, despite their proven effect and widespread
use, adverse events such as hypochlorhydria, cardiac
events and increased risk of hip fractures have led to
concerns over the safety of these drugs,7,8 resulting in a
surge of interest in identifying natural remedies that
can effectively control GERD symptoms and prevent
its complications.
Aloe vera (A. vera) is a medicinal plant with wide appli-
cations in the pharmaceutical industry for both system-
ic9,10 and dermatologic disorders.11-14 A. vera gel has
been demonstrated to possess several pharmacological
actions including antioxidant, anti-inflammatory, anal-
gesic, anti-proliferative, and anti-diabetic properties.15
Furthermore, A. vera has also shown anti-ulcer,16,17
wound-healing,18 and antimicrobial19 effects, all of
which may be relevant to the treatment of GERD and
its comorbidities. However, despite these promising
mechanisms of action and positive findings in preclini-
cal models of GERD and peptic ulcers,16,17 clinical eval-
uations of A. vera gel as a treatment for GERD have
been scarce. The present trial aimed to explore the clini-
cal efficacy of A. vera syrup compared with the stan-
dard medications omeprazole and ranitidine in patients
suffering from GERD symptoms.
METHODS
Subjects
This randomized, open-label, positive-controlled clini-
cal trial enrolled patients aged 18-65 years who were di-
agnosed with GERD and referred to the endoscopy
ward at the Baqiyatallah Hospital (Tehran, Iran). The
study protocol was approved by the institutional Ethics
Committee and written informed consent was ob-
tained from all participants. Exclusion criteria were
pregnancy, breastfeeding, and presence of hematemesis,
odynophagia, treatment-resistant GERD, other gastro-
intestinal disorders (e.g. peptic ulcer, irritable bowel
syndrome, obstructive diseases), hepatic diseases, mal-
nutrition syndrome, hematologic diseases, use of mus-
cle relaxant drugs (e.g. anticholinergic agents, calcium
channel blockers), or history of hypersensitivity to A.
vera preparations.
Treatments
Seventy-nine eligible subjects were randomly allocated
to A. vera syrup (10 mL once a day), omeprazole cap-
sule (20 mg once a day) or ranitidine tablet (150 mg in
a fasted state in the morning and 150 mg 30 min be-
fore sleep at night) for a period of 4 weeks. Randomiza-
tion was performed using a random-number table con-
trolled by the pharmacy. A. vera syrup was formulated
by the Barij Essence Pharmaceutical Co., (Mashade Ar-
dehal, Kashan, Iran), and was standardized to 5.0 mg
polysaccharide per mL of syrup.
Efficacy measures
Assessment of treatment efficacy was symptom-based.20,21
Improvements in common GERD symptoms were
measured according to a modified Reflux Disease Ques-
tionnaire,22 which is a validated, self-administered scale
that is widely used for the assessment of anti-reflux
treatment effects.23 The frequencies of eight main symp-
toms of GERD, namely heartburn, food regurgitation,
flatulence, belching, dysphagia, nausea, vomiting and
acid regurgitation, were assessed at weeks 2 and 4 of
the trial and were compared between the different treat-
ment arms.
Statistical analysis
Statistical analyses were performed using SPSS software
version 16.0 (SPSS Inc., Chicago, IL, USA). With-
in-group comparisons of the frequencies of GERD
symptoms were carried out using the binomial sign
test. Between-group comparisons were made using
Pearson's χ2 or Fisher's exact test. Quantitative data are
expressed as the mean ± standard deviation ( xˉ ± s ). In
all analyses, a two-sided P value < 0.05 was considered
to be statistically significant.
RESULTS
The demographic characteristics of the study groups in-
cluding age, sex, body mass index, educational level
and smoking habit are shown in Table 1. There were
no significant differences in any of these parameters be-
tween the groups.
The severities of GERD symptoms were assessed after
2 and 4 weeks of treatment. The baseline frequencies
of all the evaluated GERD symptoms were similar in
the A. vera, ranitidine and omeprazole groups (P >
0.05). The frequencies of all GERD symptoms were re-
duced at both 2 and 4 weeks of treatment in the A. ve-
ra group compared with baseline, with a trend towards
further improvement in the frequencies of heartburn,
flatulence and belching from weeks 2-4 of the trial (Ta-
ble 2).
In the omeprazole group, the frequencies of all assessed
symptoms were significantly reduced compared with
baseline at both time points (weeks 2 and 4) and the
frequencies of heartburn, flatulence, belching and acid
regurgitation showed further reductions at week 4 com-
pared with week 2 (Table 2).
In the ranitidine group, the frequencies of heartburn,
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flatulence, belching, nausea, vomiting and acid regurgi-
tation were significantly reduced at week 2 compared
with baseline. The frequencies of all assessed symptoms
except flatulence were significantly reduced at week 4
compared with both baseline and week 2, while flatu-
lence was reduced at week 4 compared with week 2
(Table 2).
A. vera had less effect on reducing the frequencies of
heartburn at weeks 2 and 4 compared with omepra-
zole, and at week 4 compared with ranitidine, and less
effect on flatulence at week 4 compared with omepra-
zole, and at weeks 2 and 4 compared with ranitidine.
Patients in the A. vera group also had a higher frequen-
cy of belching at week 4 compared with patients in the
omeprazole group. Frequencies of other symptoms
were comparable between the study groups.
There were two reports of adverse reactions in the A.
vera group (one vertigo and one stomachache), three in
the omeprazole group (one headache, one constipation
and one heartburn), and three in the ranitidine group
(one of constipation, two heartburn, and two diarrhea)
(Table 3). These adverse events were responsible for
two drop-outs in the ranitidine group and two in the
omeprazole group, but none in the A. vera group.
DISCUSSION
The results of the present randomized controlled trial
provide evidence for the efficacy of A. vera gel syrup in
reducing the common symptoms of GERD. This effi-
cacy of A. vera was comparable to those of the standard
drugs ranitidine and omeprazole in relation to most
symptoms. An epidemiological study in Poland report-
ed that A. vera was routinely used to treat gastric hyper-
acidity, as well as gastric and duodenal ulcers in ciga-
rette smokers.24 In an experimental study, intravenous
administration of aloctin A, a glycoprotein present in
Aloe species, was shown to reduce the secretion of gas-
Parameter
N
Female (n)
Age (years)
BMI (kg/m2)
Smoking (n)
Educational level (n) Illiterate
Under diploma
Diploma
University
Aloe vera
28
15
46±17
52±4
3
3
11
4
10
Omeprazole
27
19
48±17
26±5
3
3
11
8
5
Ranitidine
24
11
47±14
25±4
2
3
11
4
15
Note: BMI: body mass index.
Table 1 Demographic characteristics of study subjects ( xˉ ± s)
Item
Heartburn
Food regurgitation
Dysphagia
Flatulence
Belching
Nausea
Vomiting
Acid regurgitation
Aloe vera
Baseline
17
(100.0)
10
(100.0)
12
(100.0)
17
(100.0)
15
(100.0)
5
(100.0)
1
(100.0)
20
(100.0)
Week 2
4a
(23.5)
1a
(10.0)
4a
(33.3)
1a
(5.9)
2a
(13.3)
1a
(20.0)
1
(100.0)
10a
(50.0)
Week 4
5a
(29.4)
1a
(10.0)
4a
(33.3)
2a
(11.8)
3a
(20.0)
1a
(20.0)
1
(100.0)
10a
(50.0)
Omeprazole
Baseline
24
(100.0)
11
(100.0)
12
(100.0)
21
(100.0)
19
(100.0)
12
(100.0)
3
(100.0)
20
(100.0)
Week 2
13ab
(54.2)
2a
(18.2)
1a
(8.3)
5a
(23.8)
7a
(36.8)
4a
(33.3)
2a
(66.7)
12a
(60.0)
Week 4
15ab
(62.5)
2a
(18.2)
1a
(8.3)
9ac
(42.9)
10ab
(52.6)
4a
(33.3)
2a
(66.7)
13a
(65.0)
Ranitidine
Baseline
25
(100.0)
16
(100.0)
9
(100.0)
23
(100.0)
21
(100.0)
15
(100.0)
6
(100.0)
24
(100.0)
Week 2
9a
(36.0)
1
(6.3)
0
(0.0)
12ac
(52.1)
3a
(14.3)
8a
(53.3)
2a
(33.3)
10a
(41.7)
Week 4
13ab
(52.0)
2a
(12.5)
2
(12.5)
7ac
(30.4)
7a
(30.4)
10a
(66.7)
4a
(66.7)
16a
(66.7)
Notes: GERD: gastroesophageal reflux disease. aP < 0.05: within group comparison with respect to baseline value; bborderline significant
difference versus A. vera group at the respective time point; cbetween-group comparison at respective time point (week 2 or 4) in the A. ve-
ra group.
Table 2 Frequency of GERD symptoms in the study groups at baseline, and at weeks 2 and 4 of the trial [n (%)]
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tric juice, acid and pepsin, and inhibit acute gastric le-
sions in rats.25 Another study in rats with gastric ulcers
showed that treatment with A. vera reduced leukocyte
adherence to postcapillary venules, elevated serum con-
centrations of interleukin-10, and reduced serum tu-
mor necrosis factor-α (TNF-α). In addition, histopath-
ological examination revealed reduced gastric inflam-
mation and ulcer size, and enhanced epithelial cell pro-
liferation and gastric gland growth following A. vera
treatment. These protective effects of A. vera were com-
parable to those of the standard drug sucralfate.17
Oxidative stress and inflammation have been implicat-
ed as key factors in the pathophysiology of GERD.26
The efficacy of A. vera gel in reducing the symptoms
of GERD might thus be partly attributable to its anti-
oxidant and anti-inflammatory ingredients.27 A. vera
possesses antioxidant capacity and was shown to reduce
oxidative damage in several experimental models, in-
cluding CCL4-induced hepatotoxicity and chronic liver
fibrosis.28 There are several mechanisms responsible for
the antioxidant actions of A. vera, including scaveng-
ing of free radicals, reduction of lipid peroxidation and
up-regulation of antioxidant enzymes.27,29,30 In addition,
leukocyte infiltration and circulating concentrations of
TNF-α were significantly reduced following adminis-
tration of A. vera to Helicobacter pylori-infected
mice.31 Of relevance to its role in gastrointestinal disor-
ders, A. vera has shown strong antimicrobial effects
against H. pylori,19 as well as having a reducing effect
on gastric acid secretion.32 This effect has been pro-
posed to be associated with the action of lectins present
in A. vera, which inhibit aminopyrin uptake by pari-
etal cells, thereby reducing acid secretion.33
The results of the present study indicated that con-
sumption of A. vera was safe and well tolerated, and
unlike the comparator treatments, its use was not asso-
ciated with treatment withdrawal. This plant has been
classified as Generally Recognized As Safe based on
clinical evidence and a long ethnobotanical history sup-
porting its safety. Furthermore, A. vera preparations are
relatively inexpensive and widely available, and have
been shown to possess therapeutic activities against sev-
eral other disorders that commonly accompany
GERD, such as peptic ulcers,16,17 irritable bowel syn-
drome,34 ulcerative colitis,35 type 2 diabetes9,10 and dys-
lipidemia.9,10
To conclude, the results of this pilot, randomized con-
trolled trial indicate that A. vera syrup provides a safe
and effective treatment for reducing the frequency of
GERD symptoms. A. vera should therefore be suggest-
ed as an effective supplement in patients suffering from
GERD. Further studies are needed to investigate the
impact of treatment with higher doses of A. vera, and
also to explore the efficacy of A. vera treatment in re-
ducing long-term complications of GERD such as Bar-
rett's esophagus, esophageal strictures, erosive esophagi-
tis and esophageal carcinoma.
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